Tarsus Pharmaceuticals (TARS)
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye c...
- Open
- 71.720
- High
- 73.135
- Low
- 71.260
- Prev. Close
- 71.490
- Volume
- 636.34K
- Turnover
- 46.19M
- Avg Price
- 72.585
- Bid/Ask Ratio
- --
- Amplitude
- 2.62%
- 52wk High
- 85.250
- Volume Ratio
- 0.69
- Turnover Ratio
- 1.95%
Tarsus Pharmaceuticals Analyst Rating
View moreForecast & Rating
Aug 12, 2026Price forecast
$94.8630.48%
Forecast & RatingStrong buy
7analysts
- Strong buy100.00%
- Buy0.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- Market Beat · Aug 13 at 04:22 AM
Wasatch Advisors LP Buys New Holdings in Tarsus Pharmaceuticals, Inc. $TARS
- Market Beat · Aug 8 at 02:39 AM
Tarsus Pharmaceuticals, Inc. $TARS Shares Sold by Assenagon Asset Management S.A.
- Pharmaceutical Technology · Aug 7 at 06:13 AM
Tarsus joins Stargardt race to market with $800m Alkeus takeover
- Tip Ranks · Aug 6 at 07:13 PM
Tarsus Pharmaceuticals Balances XDEMVY Surge With Retina Bet
- PUBT · Aug 6 at 10:36 AM
Tarsus Q2 net sales climb 69% to USD 173.9 million
- StockTitan · Aug 5 at 10:03 PM
Tarsus Reports Second Quarter 2026 Financial Results, Advances Next Phase of Growth | TARS Stock News
